论文部分内容阅读
病毒巨噬细胞炎症蛋白II(vMIP-II)是一种广谱趋化因子受体拮抗剂,它所拮抗的趋化因子受体被认为是不同的人免疫缺陷病毒株(Human immunodeficiency virus,HIV)进入靶细胞的辅受体。虽然理论上vMIP-II是一个广谱的HIV抑制剂,但vMIP-II的抗HIV感染作用却少有报道,特别是体内研究。本研究利用一个有效的SIV-mac251感染食蟹猴模型来评价vMIP-II的体内抗HIV感染作用,结果显示vMIP-II能够有效地并呈剂量依赖性地降低食蟹猴血浆病毒载量,同时对宿主免疫功能具有保护作用。这些结果表明vMIP-II是一种有效的抗HIV物质,可以作为一类新型的抗HIV先导药物,也为研发靶向病毒进入的新药提供了进一步的理论支持。
Viral macrophage inflammatory protein II (vMIP-II) is a broad-spectrum chemokine receptor antagonist whose antagonized chemokine receptor is thought to be a distinct human immunodeficiency virus (HIV ) Into the target cell’s co-receptor. Although vMIP-II is theoretically a broad-spectrum HIV inhibitor, the anti-HIV infection of vMIP-II is rarely reported, especially in vivo. In this study, an effective model of SIV-mac251 infection in cynomolgus monkeys was used to evaluate the in vivo anti-HIV infection effect of vMIP-II. The results showed that vMIP-II can effectively and dose-dependently reduce cynomolgus monkey plasma viral load, meanwhile, The host immune function has a protective effect. These results indicate that vMIP-II is a potent anti-HIV substance that can be used as a new class of anti-HIV leader and further theoretical support for the development of new drugs targeting viral entry.